Clinical trial
A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering ALECSAT to Pancreas Cancer Patients
NCT01984658 is registered in ClinicalTrials.gov with CytoVac A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering ALECSAT to Pancreas Cancer Patients
- Lead sponsor
- CytoVac A/S
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 31, 2013
- Completion date
- September 30, 2015
- Enrollment
- 10 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
pancreatic cancer